A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2017
At a glance
- Drugs KLH 2109 (Primary)
- Indications Endometriosis
- Focus Therapeutic Use
- Acronyms EDELWEISS
- Sponsors ObsEva
- 07 Nov 2017 According to an ObsEva media release, approximately 330 patients are expected to be randomized, and primary endpoint efficacy results continue to be anticipated in mid-2018.
- 07 Nov 2017 Status changed from recruiting to active, no longer recruiting, according to an ObsEva media release.
- 15 Aug 2017 According to an ObsEva media release, enrollment in the European sites is complete while US recruitment remains ongoing. Completion of enrollment is expected in late 2017 or early 2018, with data expected from the first 12-week evaluation period around mid-2018.